Abstract▴ Valganciclovir is a prodrug of ganciclovir which has been developed for the
treatment of cytomegalovirus (CMV) retinitis in patients with AIDS.▴ Oral valganciclovir is …

Valganciclovir (Valcyte™) is an orally administered prodrug of the standard anti-
cytomegalovirus (CMV) drug ganciclovir. Valganciclovir is as effective as intravenous …

Oral valganciclovir recently was approved by the Food and Drug Administration for treatment
of cytomegalovirus (CMV) retinitis. We performed MEDLINE (June 1998–May 2002) and …

Objective Ganciclovir is commonly used in the treatment of cytomegalovirus (CMV) disease
in patients who are immunocompromised and for the prevention of CMV disease in solid …

Oral valganciclovir is a new and highly efficacious alternative to the chronic administration of
ganciclovir in the treatment of cytomegalovirus (CMV) retinitis in HIV-infected patients. In …

OBJECTIVE: To review the pharmacology, pharmacokinetics, and preliminary clinical data
for valganciclovir, a new oral agent for the therapy of cytomegalovirus (CMV) retinitis. DATA …

Valganciclovir, an oral prodrug of the anti-cytomegalovirus (CMV) agent ganciclovir, was
evaluated in a single-arm open-label safety study. AIDS patients (median CD4 lymphocyte …

Background Valganciclovir is an orally administered prodrug that is rapidly hydrolyzed to
ganciclovir. We compared the effects of oral valganciclovir with those of intravenous …

Abstract A phase I/II study evaluated the pharmacokinetics, tolerability, and antiviral activity
of oral ganciclovir in persons infected with human immunodeficiency virus (HIV). Oral …

Oral ganciclovir has recently been approved for use in long-term maintenance therapy in the
treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients. Although oral …